Source-grounded facts extracted from Invivyd, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Invivyd, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-19 meeting.
“Proposal 2: The stockholders of the Company ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with votes cast as follows: For Against Abstain Broker Non-Votes 222,576,623 80,390 44,315 —”
Invivyd, Inc. shareholders approved Election of directors for a one-year term expiring at the 2027 Annual Meeting at the 2026-05-19 meeting.
“Proposal 1: The stockholders of the Company elected Tamsin Berry, Paul B. Bolno, M.D., Marc Elia, Terrance McGuire, Kevin F. McLaughlin and Ajay Royan as directors for a one-year term expiring at the Company’s 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal.”
Invivyd, Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 14, 2026, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026, and recent business highlights.”
Invivyd, Inc. reported financial results for the fiscal year ended December 31, 2025.
“Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights.”
Invivyd, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $17.2 million.
“Achieved Q4 2025 PEMGARDA ® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter”
Invivyd, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 21, 2025, Invivyd, Inc. (the “Company”) received a deficiency letter (the “ Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for a period of 30 consecutive business days, the bid price for the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Letter has no immediate effect on the listi”
Invivyd, Inc. incurred term loan of up to $30 million with Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company at the greater of (x) the Wall Street Journal prime rate minus 0.25% (subject to a maturing March 1, 2029.
“On April 18, 2025 (the “Closing Date”), Invivyd, Inc. (the “Company”), entered into a Loan and Security Agreement (the “Loan Agreement”), between the Company, as borrower, and Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company, as lender (the “Lender”). The Loan Agreement provides for a senior secured term loan facility in an aggregate principal amount of up to $30 million”
Ajay Royan was appointed as director at Invivyd, Inc..
“On March 22, 2025, the Board of Directors (the “Board”) of Invivyd, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Ajay Royan as a director, effective immediately, with his term expiring at the Company’s 2025 annual meeting of stockholders.”
Invivyd, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“December 27, 2024, Invivyd, Inc. (the “Company”) received a deficiency letter (the “ Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock, $0.0001 par value per share (the “Common Stock”), had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Letter has no immediate effect on the l”
Sara Cotter resigned as Director at Invivyd, Inc..
“On November 27, 2024, Sara Cotter notified Invivyd, Inc. (the “Company”) of her decision to resign from the Board of Directors of the Company and all committees thereof, effective immediately.”
William Duke, Jr. was appointed as Principal Executive Officer at Invivyd, Inc..
“Effective May 30, 2024, William Duke, Jr., the Company’s Chief Financial Officer, will serve as the Company’s “principal executive officer”.”
Jeremy Gowler departed as Interim Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer at Invivyd, Inc..
“Jeremy Gowler, the Interim Chief Executive Officer, Chief Operating Officer and Chief Commercial Officer of Invivyd, Inc. (the “Company”), ceased serving as an executive officer and as the Company’s “principal executive officer,” effective as of May 30, 2024, with his employment terminating on June 29, 2024.”
Invivyd, Inc. reported the quarter ended March 31, 2024 results: net income Net loss was $43.5 million for the quarter ended March 31, 2024, compared to $35.3 million for the comparable period in, EPS Basic and diluted net loss per share was $0.38 for the quarter ended March 31, 2024, compared to $0.32 for the comparabl. Guidance reaffirmed.
“On May 9, 2024, Invivyd, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024, and recent business highlights.”
Jeremy Gowler was appointed as Interim Chief Executive Officer at Invivyd, Inc..
“the Board appointed Jeremy Gowler, the Company's current Chief Operating Officer and Chief Commercial Officer, as the Company's Interim Chief Executive Officer”
David Hering resigned as Director at Invivyd, Inc..
“Mr. Hering has also resigned from the Board pursuant to the terms of the Hering Employment Agreement.”
Invivyd, Inc. reported the year ended December 31, 2023 results: net income Net loss was $198.6 million for the year ended December 31, 2023, EPS Basic and diluted net loss per share was $1.81 for the year ended December 31, 2023.
“Invivyd, Inc. (the "Company") issued a press release announcing its financial results for the year ended December 31, 2023”
Tomas Heyman departed as Director at Invivyd, Inc..
“On February 5, 2024, Tomas Heyman, a member of the Board of Directors of Invivyd, Inc. (the “Company”), informed the Company of his decision not to stand for re-election when his term expires at the Company’s 2024 annual meeting of stockholders.”
Invivyd, Inc. entered into Controlled Equity Offering℠ Sales Agreement with Cantor Fitzgerald & Co. valued at up to $75.0 million (effective 2023-12-22).
“On December 22, 2023, Invivyd, Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor”), pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of the Company’s common stock, par value $0.0001 per share (the “Shares”).”
Invivyd, Inc. reported quarter ended September 30, 2023 results: net income Net loss was $39.4 million, EPS Basic and diluted net loss per share was $0.36.
“Third Quarter 2023 Financial Results: • Cash position: Cash, cash equivalents and marketable securities were $264.9 million as of September 30, 2023. • Cash runway: Based on current operating plans, Invivyd continues to expect its existing total cash, cash equivalents and marketable securities will enable the company to fund its operating expenses into the fourth quarter of 2024, excluding potential contribution of commercial product revenue if a mAb candidate is authorized or approved. • Research & development (R&D) expenses (including in-process research & development): R&D expenses were $30.2 million for the quarter ended September 30, 2023, compared to $34.1 million for the comparable period of 2022. The decrease is primarily attributable to higher clinical trial costs in 2022 due to ongoing adintrevimab clinical trials, with no comparable costs during the same period in 2023 due to the wind-down of adintrevimab clinical trials, partially offset by clinical trial costs associated w”
William Duke was appointed as Chief Financial Officer at Invivyd, Inc..
“On September 5, 2023, Invivyd, Inc. (the “Company”) announced the appointment of William Duke, age 51, as the Company’s Chief Financial Officer, effective as of September 1, 2023”
Invivyd, Inc. reported financial results for quarter ended June 30, 2023.
“On August 10, 2023, Invivyd, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the quarter ended June 30, 2023.”
Sara Cotter was appointed as director at Invivyd, Inc..
“appointed Sara Cotter as a director to fill the resulting vacancy, effective immediately”
Invivyd, Inc.: Amended Bylaws to remove references to the classified Board structure and conform director removal provisions with the Certificate of Amendment (effective 2023-05-23).
“On May 23, 2023, an amendment to the Company’s Amended and Restated Bylaws (the “Bylaws Amendment”) became effective upon the filing and effectiveness of the Certificate of Amendment. The Bylaws Amendment removes references to the classified Board structure and conforms the director removal provisions of the Company’s Amended and Restated Bylaws with the Certificate of Amendment.”
Invivyd, Inc.: Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to declassify the Board of Directors and allow removal of directors with or without cause by majority vote of the outstanding voting shares (effective 2023-05-23).
“As described in Item 5.07 below, at the Annual Meeting of Stockholders of Invivyd, Inc. (the “Company”) held on May 23, 2023 (the “Annual Meeting”), the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) to (i) declassify the Board of Directors of the Company (the “Board”), with each elected director serving for a one-year term until the next year’s annual meeting, and (ii) provide that directors of the Company may be removed with or without cause by the affirmative vote of the holders of at least a majority of the voting power of all then-outstanding shares of capital stock of the Company entitled to vote generally at an election of directors (the “Declassification Amendment”).”
Invivyd, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-23 meeting.
“The stockholders of the Company ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, with votes cast as follows: For Against Abstain Broker Non-Votes 103,977,497 87,436 7,188 —”
Invivyd, Inc. shareholders approved Election of directors Christine Lindenboom and Terrance McGuire for a three-year term at the 2023-05-23 meeting.
“The stockholders of the Company elected Christine Lindenboom and Terrance McGuire as directors for a three-year term expiring at the 2026 Annual Meeting of Stockholders”
Invivyd, Inc. shareholders approved Declassification Amendment to declassify the Board of Directors and provide for director removal with or without cause at the 2023-05-23 meeting.
“The stockholders of the Company approved the Declassification Amendment, with votes cast as follows: For Against Abstain Broker Non-Votes 100,169,285 91,225 799 3,810,812”
Invivyd, Inc. reported the year ended December 31, 2022 results: net income $241.3 million.
“Net loss was $241.3 million for the year ended December 31, 2022”
Jeremy Gowler was appointed as Chief Operating Officer and Chief Commercial Officer at Invivyd, Inc..
“On December 6, 2022, Invivyd, Inc. (the “Company”) announced the appointment of Jeremy Gowler, age 46, as the Company’s Chief Operating Officer and Chief Commercial Officer, effective as of December 16, 2022 (the “Gowler Effective Date”).”
Invivyd, Inc. entered into Master Services Agreement with Population Health Partners, L.P. valued at aggregate fee of $3,000,000 (effective 2022-11-15).
“On November 15, 2022 (the “Effective Date”), Invivyd, Inc. (the “Company”) entered into a Master Services Agreement with Population Health Partners, L.P. (“PHP”), pursuant to which PHP agreed to provide services and create deliverables for the Company as agreed between the Company and PHP and set forth in one or more work orders under such agreement (the “MSA”).”
Invivyd, Inc. reported the third quarter ended September 30, 2022 results: net income $45.1 million, EPS $0.42 per share.
“Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today announced financial results and business highlights for the third quarter ended September 30, 2022.”
Redonda Miller resigned as Director at Invivyd, Inc..
“On October 20, 2022, Redonda Miller, M.D., M.B.A. notified Invivyd, Inc. (the “Company”) of her decision to resign from the Board of Directors of the Company (the “Board”) and all committees thereof, effective immediately.”
Frederick W. Driscoll was appointed as Interim Chief Financial Officer at Invivyd, Inc..
“the Board of Directors of the Company (the “Board”) appointed Frederick W. Driscoll, age 71, as the Company’s Interim Chief Financial Officer and designated him as the Company’s principal financial officer and principal accounting officer, effective as of October 13, 2022.”
Jane Henderson departed as Chief Financial & Business Officer at Invivyd, Inc..
“Jane Henderson, the Company’s Chief Financial & Business Officer, will cease serving as an executive officer, as well as the Company’s principal financial officer and principal accounting officer, effective as of October 13, 2022”
David Hering was appointed as Chief Executive Officer and Director at Invivyd, Inc..
“On July 5, 2022 (the “Effective Date”), the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed David Hering, M.B.A., age 47, as the Company’s Chief Executive Officer.”
Howard Mayer resigned as Director at Invivyd, Inc..
“On June 24, 2022, Howard Mayer, M.D. notified Adagio Therapeutics, Inc. (the “Company”) of his decision to resign from the board of directors of the Company and all committees thereof, effective immediately.”
Anand Shah resigned as director at Invivyd, Inc..
“On June 17, 2022, Anand Shah, M.D. notified Adagio Therapeutics, Inc. (the “Company”) of his decision to resign from the board of directors of the Company and all committees thereof, effective immediately following adjournment of the Company’s 2022 annual meeting of stockholders, which will be held on June 22, 2022.”
David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..
“Following Dr. Gerngross’s resignation, on February 23, 2022, the Board appointed David Hering to serve as Interim Chief Executive Officer.”
Tillman U. Gerngross resigned as Chief Executive Officer and President at Invivyd, Inc..
“On February 23, 2022, Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer and President of Adagio Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company.”
Jane Pritchett Henderson was appointed as Chief Business Officer at Invivyd, Inc..
“On March 18, 2022, the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed Jane Pritchett Henderson, the Company’s principal financial officer, to serve as the Company’s Chief Business Officer.”
Lynn Connolly resigned as Chief Medical Officer at Invivyd, Inc..
“Lynn Connolly, M.D., Ph.D., Chief Medical Officer of Adagio Therapeutics, Inc. (the “Company”), has resigned her position, effective as of March 25, 2022, to tend to family obligations.”
David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..
“Following Dr. Gerngross’s resignation, on February 23, 2022, the Board appointed David Hering to serve as Interim Chief Executive Officer.”
Tillman U. Gerngross resigned as Chief Executive Officer and President at Invivyd, Inc..
“On February 23, 2022, Tillman U. Gerngross, Ph.D. resigned as Chief Executive Officer and President of Adagio Therapeutics, Inc. (the “Company”) and as a member of the Board of Directors (the “Board”) of the Company.”
David Hering was appointed as Interim Chief Executive Officer at Invivyd, Inc..
“The Board intends to appoint Mr. David Hering, M.B.A. (who currently serves as the Company’s Chief Operating Officer) as Interim Chief Executive Officer of the Company.”
Tillman Gerngross resigned as Chief Executive Officer at Invivyd, Inc..
“On February 14, 2022, Tillman Gerngross, Ph.D. communicated to the Chairperson of the Board of Directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) that he agreed in principle to resign from his position as Chief Executive Officer of the Company.”
Redonda Miller was appointed as director at Invivyd, Inc..
“On November 19, 2021, the board of directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed Ms. Ellen Marram and Dr. Redonda Miller to serve as directors of the Company.”
Ellen Marram was appointed as director at Invivyd, Inc..
“On November 19, 2021, the board of directors (the “Board”) of Adagio Therapeutics, Inc. (the “Company”) appointed Ms. Ellen Marram and Dr. Redonda Miller to serve as directors of the Company.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.